Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria

BackgroundSince summer 2024, passive immunization with nirsevimab (Beyfortus®) has been recommended for all infants in Austria to prevent severe respiratory syncytial virus (RSV) infection. Maternal vaccination with RSVpreF (Abrysvo®), which provides transplacental protection, became available in au...

Descrición completa

Detalles Bibliográficos

Principais autores:	Michaela Höck, Wegene Borena, Jürgen Brunner, Karina Wechselberger, Johanna Scheiring, Elisabeth Ralser, Ulrike Pupp Peglow, Peter Wöckinger, Elisabeth D’Costa, Verena Kaiser, Klaus Kapelari, Gisa Gerold, Thomas Müller, Ursula Kiechl-Kohlendorfer, Elke Griesmaier
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2025-10-01
Series:	Frontiers in Public Health
Assuntos:	nirsevimab RSV newborn RSVpreF vaccine acceptance
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fpubh.2025.1686581/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!